CBD drugmaker GW Pharmaceuticals poised to raise $300 million

Article was originally posted here

GW Pharmaceuticals is setting out to sell $300 million worth of U.S. depository shares. The London-based company’s announcement comes on the heels of the U.S. Drug Enforcement Administration’s move to take some cannabidiol products off the most restrictive class of controlled substances. That change will allow Epidiolex – a CBD drug manufactured by GW Pharmaceuticals to treat rare […]

CBD drugmaker GW Pharmaceuticals poised to raise $300 million is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

This post is from Marijuana Business Daily. We encourage our readers to continue reading the full article from the original source here.